Literature DB >> 30833488

Adverse Drug Reactions in an Oncological Population: Prevalence, Predictability, and Preventability.

Amanda Hanora Lavan1,2, Deirdre O'Mahony3,4, Mary Buckley2, Denis O'Mahony3,2, Paul Gallagher3,2.   

Abstract

BACKGROUND: Our goal was to determine (a) the prevalence of multimorbidity and polypharmacy in patients with cancer and (b) the prevalence, predictability, and preventability of adverse drug reactions (ADRs) causing/contributing to hospitalization.
MATERIALS AND METHODS: We conducted a 12-month prospective observational study of patients aged ≥16 years admitted to an oncology center. Older adults were aged ≥70 years.
RESULTS: We enrolled 350 patients: 52.3% (n = 183) female, mean age 63.6 years (SD 12.1), 36.6% (n = 121) aged ≥70 years. Multimorbidity (≥2 conditions) was identified in 96.9%; 68% had ≥5 conditions. The median number of medications was 6 (interquartile range [IQR] 4-8); 47% were prescribed ≥6 medications and 11.4% ≥11 medications. Older adults had higher numbers of comorbid conditions (7 [IQR 5-10] vs. 5 [IQR 3-7]) and were prescribed more medications (median 7 [IQR 4-9] vs. 4 [IQR 2-7]). ADRs caused/contributed to hospitalization in 21.5% (n = 75): 35.8% (n = 72) of emergency admissions and 4.7% (n = 3) of elective admissions. The most common ADRs were neutropenia with infection (25.3%), dyspepsia/nausea/vomiting (20%), and constipation (20%). Causative medications included systemic anticancer therapies (SACTs; 53.3%), opioids (17.3%), corticosteroids (6.7%), and nonsteroidal anti-inflammatory drugs (5.3%). ADR prevalence was similar in older and younger adults secondary to SACTs (8.3% vs. 13.1%), non-cancer medications (10.7% vs. 8.3%), and both (0% vs. 1.3%). ADRs were predictable in 89.3% (n = 67), definitely avoidable in 29.3% (n = 22), and possibly avoidable in 33.3% (n = 25). No association was identified between ADRs and age, gender, daily medication number, length of stay, or death. No ADR predictor variables were identified by logistic regression.
CONCLUSION: More than 21% of admissions to an oncology service are ADR-related. ADRs are caused by both SACTs and non-cancer-specific medications. The majority are predictable; ≥60% may be preventable. Patients with cancer have high levels of multimorbidity and polypharmacy, which require vigilance for related adverse outcomes. IMPLICATIONS FOR PRACTICE: A diagnosis of cancer often occurs in patients with multimorbidity and polypharmacy. Cancer can cause an altered physiological environment, placing patients at risk of drug-drug interactions, drug-disease interactions, and adverse drug reactions (ADRs). This study identified that ADRs caused or contributed to one in five hospital admissions of patients with cancer. ADRs were caused by systemic anticancer therapies (SACTs) in 53.3% of cases and non-cancer medications in 45.4% of cases, and a combination of both in 1.3%. ADRs occurred in similar frequencies in older and younger patients secondary to SACTs (8.3% vs. 13.1%, p = .295), non-SACTs (10.7% vs. 8.3%, p = .107), and a combination of both (0% vs. 1.3%, p = .240). The majority of ADRs were predictable (89.3%) and potentially preventable (62.6%). These findings support the need for increased awareness of medication-related adversity in patients with cancer and interventions to minimize their occurrence, thus supporting the American Society of Clinical Oncology guidelines that recommend adults ≥65 years of age receiving chemotherapy have geriatric assessment to identify medical and medication issues. © AlphaMed Press 2019.

Entities:  

Keywords:  Adverse drug reactions; Clinical oncology; Hospitalization; Multimorbidity; Polypharmacy

Year:  2019        PMID: 30833488      PMCID: PMC6738308          DOI: 10.1634/theoncologist.2018-0476

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  33 in total

1.  Heart disease and stroke statistics--2010 update: a report from the American Heart Association.

Authors:  Donald Lloyd-Jones; Robert J Adams; Todd M Brown; Mercedes Carnethon; Shifan Dai; Giovanni De Simone; T Bruce Ferguson; Earl Ford; Karen Furie; Cathleen Gillespie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; P Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary M McDermott; James Meigs; Dariush Mozaffarian; Michael Mussolino; Graham Nichol; Véronique L Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Véronique L Roger; Randall Stafford; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2009-12-17       Impact factor: 29.690

2.  Potentially inappropriate prescribing and cost outcomes for older people: a national population study.

Authors:  Caitriona Cahir; Tom Fahey; Mary Teeling; Conor Teljeur; John Feely; Kathleen Bennett
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

3.  Cumulative illness rating scale.

Authors:  B S Linn; M W Linn; L Gurel
Journal:  J Am Geriatr Soc       Date:  1968-05       Impact factor: 5.562

4.  Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention.

Authors:  J Hallas; B Harvald; L F Gram; E Grodum; K Brøsen; T Haghfelt; N Damsbo
Journal:  J Intern Med       Date:  1990-08       Impact factor: 8.989

5.  STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation.

Authors:  P Gallagher; C Ryan; S Byrne; J Kennedy; D O'Mahony
Journal:  Int J Clin Pharmacol Ther       Date:  2008-02       Impact factor: 1.366

6.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.

Authors:  Munir Pirmohamed; Sally James; Shaun Meakin; Chris Green; Andrew K Scott; Thomas J Walley; Keith Farrar; B Kevin Park; Alasdair M Breckenridge
Journal:  BMJ       Date:  2004-07-03

Review 7.  Multimorbidity and polypharmacy in the elderly: lessons from REPOSI.

Authors:  Pier Mannuccio Mannucci; Alessandro Nobili
Journal:  Intern Emerg Med       Date:  2014-08-28       Impact factor: 3.397

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 9.  STOPP/START criteria for potentially inappropriate prescribing in older people: version 2.

Authors:  Denis O'Mahony; David O'Sullivan; Stephen Byrne; Marie Noelle O'Connor; Cristin Ryan; Paul Gallagher
Journal:  Age Ageing       Date:  2014-10-16       Impact factor: 10.668

10.  Polypharmacy: misleading, but manageable.

Authors:  Reamer L Bushardt; Emily B Massey; Temple W Simpson; Jane C Ariail; Kit N Simpson
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

View more
  5 in total

1.  Prevalence of Potential Pharmacological Interactions in Patients Undergoing Systemic Chemotherapy in a Tertiary Hospital.

Authors:  Eric Diego Turossi-Amorim; Bruna Camargo; Fabiana Schuelter-Trevisol
Journal:  Hosp Pharm       Date:  2022-04-02

2.  Frequency, nature, severity and preventability of adverse drug reactions arising from cancer chemotherapy in a teaching hospital.

Authors:  Saravana Kumar Ramasubbu; Rajesh K Pasricha; Uttam K Nath; Biswadeep Das
Journal:  J Family Med Prim Care       Date:  2020-07-30

3.  Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management.

Authors:  Audrey Bellesoeur; Ithar Gataa; Pascaline Boudou-Rouquette; Audrey Thomas-Schoemann; Anne Jouinot; Sarah El Mershati; Anne-Catherine Piketty; Camille Tlemsani; David Balakirouchenane; Anthia Monribot; Michel Vidal; Rui Batista; Sixtine de Percin; Clémentine Villeminey; Jérôme Alexandre; François Goldwasser; Benoit Blanchet
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-24       Impact factor: 3.333

4.  Novel pH-responsive nanohybrid for simultaneous delivery of doxorubicin and paclitaxel: an in-silico insight.

Authors:  Ehsan Alimohammadi; Reza Maleki; Hossein Akbarialiabad; Mohammad Dahri
Journal:  BMC Chem       Date:  2021-02-11

5.  Clinical significance of potential drug-drug interactions in older adults with psychiatric disorders: a retrospective study.

Authors:  Yu Liu; Man Yang; Yaping Ding; Huanqiang Wang; Hailin Zhang; Dandan Wang; Tianchi Zhuang; Minghui Ji; Yan Cui; Hong Wang
Journal:  BMC Psychiatry       Date:  2022-08-22       Impact factor: 4.144

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.